Scholar Rock Holding (SRRK) Cash from Investing Activities Growth (1y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -114.28% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 826.39% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -674.01% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -166.24% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -122.45% |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | -115.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -115.44% |
| Dec 31, 2025 | 119.95% |
| Sep 30, 2025 | 69.08% |
| Jun 30, 2025 | 68.83% |
| Mar 31, 2025 | 3.50% |
| Dec 31, 2024 | -677.50% |
| Sep 30, 2024 | 516.71% |
| Jun 30, 2024 | 432.14% |
| Mar 31, 2024 | -62.90% |
| Dec 31, 2023 | -32,733.77% |
| Sep 30, 2023 | 94.19% |
| Jun 30, 2023 | -134.23% |
| Mar 31, 2023 | 227.50% |
| Dec 31, 2022 | -99.74% |
| Sep 30, 2022 | -4,538.65% |
| Jun 30, 2022 | -43.66% |
| Mar 31, 2022 | -412.88% |
| Dec 31, 2021 | 124.02% |
| Sep 30, 2021 | 109.15% |
| Jun 30, 2021 | 102.99% |
| Mar 31, 2021 | -59.78% |
| Dec 31, 2020 | -678.25% |
| Sep 30, 2020 | 50.29% |
| Jun 30, 2020 | 84.47% |
| Mar 31, 2020 | 273.24% |
| Dec 31, 2019 | 134.80% |
| Sep 30, 2019 | -11,968.39% |
| Jun 30, 2019 | -15.23% |
| Mar 31, 2019 | -37.26% |
| Dec 31, 2018 | -1,133.21% |
| Sep 30, 2018 | -106.66% |